Public trial registry of the CCC-Munich

Trial PHERGain_MedOPP096

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
PHERGain_MedOPP096
World
Full title
:

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer:
FDG-PET response-adapted strategy. The PHERGain study

World
Responsible organization
:
Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Breastcancer
Trial design
World
Phase
:
II
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
World
Institutional review board - vote date
:
2018-02-15
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy line
:
1
World
Therapy
:

Zielgerichtet - Therapieart: neoadjuvant

Participants
Function Prename Surname Organization
World Responsible contact Johannes Ettl Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany Magnifier